Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions

Annals of Nuclear Medicine

Volumn 27, Issue 2, 2013, Pages 163-169

  Nakayama, Michihiro ^a   Okizaki, Atsutaka ^a   Ishitoya, Shunta ^a   Sakaguchi, Miki ^a   Sato, Junichi ^a   Aburano, Tamio ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

18F FDG PET CT; Benign lymph node; Dual time point imaging; Lymphoma; Standardized uptake value

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TRACER;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOACTIVITY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; T CELL LYMPHOMA;

AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHOMA; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; ROC CURVE; TIME FACTORS;

EID: 84880702616     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0669-1     Document Type: Article

References (36)

1. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med. 2006;47:1326-34.
2. Shinya T, Fujii S, Asakura S, Taniguchi T, Yoshio K, Alafate A, et al. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma. Ann Nucl Med. 2012;13 [Epub ahead of print].
3. Ahmadzadehfar H, Rodrigues M, Zakavi R, Knoll P, Mirzaei S. Prognostic significance of the standardized uptake value of pre-therapeutic (18)F-FDG PET in patients with malignant lymphoma. Med Oncol. 2011;28:1570-6.
4. Kakhki VR. Positron emission tomography in the management of lung cancer. Ann Thorac Med. 2007;2:69-76.
5. Schrepfer T, Haerle SK, Strobel K, Schaefer N, Hälg RA, Huber GF. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas. Laryngoscope. 2010;120:937-44.
6. Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. Radiographics. 2004;24:523-43.
7. Tamura M, Oda M, Matsumoto I, Waseda R, Watanabe G. Pattern and predictors of false positive lymph node involvement on positron emission tomography in patients with non-small cell lung cancer. Thorac Cardiovasc Surg. 2012;60:105-10.
8. Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, et al. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging. 2005;32:749-56.
9. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61-77.
10. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual-time-point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-7.
11. Sonet A, Graux C, Nollevaux MC, Krug B, Bosly A, Vander Borght T. Unsuspected FDG-PET findings in the follow-up of patients with lymphoma. Ann Hematol. 2007;86:9-15.
12. Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica. 2007;92:771-7.
13. Maayan H, Ashkenazi Y, Nagler A, Izbicki G. Sarcoidosis and lymphoma: case series and literature review. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:146-52.
14. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluori-d- glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005;104:1066-74.
15. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica. 2006;91:522-9.
16. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual-time-point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345-8.
17. Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871-5.
18. Suga K, Kawakami Y, Hiyama A, Sugi K, Okabe K, Matsumoto T, et al. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time-point PET/CT scan. Ann Nucl Med. 2009;23:523-31.
19. Mavi A, Urhan M, Yu JQ, Zhuang H, Houseni M, Cermik TF, et al. Dual-time-point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47:1440-6.
20. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed (18)F-fluoro-2-deoxy-d-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000;89:2547-54.
21. Tian R, Su M, Tian Y, Li F, Li L, Kuang A, et al. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions. Skeletal Radiol. 2009;38:451-8.
22. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med. 2005;46:1819-24.
23. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35:1308-12.
24. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22-30.
25. Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2009;30:594-601.
26. Bedigian MP, Benard F, Smith RJ, Karp JS, Alavi A. Whole-body positron emission tomography for oncology imaging using singles transmission scanning with segmentation and ordered subsets-expectation maximization (OS-EM) reconstruction. Eur J Nucl Med. 1998;25:659-61.
27. Papajík T, Mysliveček M, Sedová Z, Buriánková E, Procházka V, Koranda P, et al. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma. Eur J Haematol. 2011;86:32-7.
28. Wu X, Pertovaara H, Korkola P, Vornanen M, Eskola H, Kellokumpu-Lehtinen PL. Glucose metabolism correlated with cellular proliferation in diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;53:400-5.
29. Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696-703.
30. Gupta N, Gill H, Graeber G, Bishop H, Hurst J, Stephens T. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest. 1998;114:1105-11.
31. Nagamachi S, Hoshi H, Jinnouchi S, Ohnishi T, Flores LG 2nd, Futami S, Nakahara H, et al. 201TL SPECT for evaluating head and neck cancer. Ann Nucl Med. 1996;10:105-11.
32. Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, et al. Dual-phase 18F-fluoro-2-deoxy-d-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2005;32:389-97.
33. Uesaka D, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Sasaki M, et al. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer. J Nucl Med. 2008;49:1606-12.
34. Chun H, Kim CK, Krynckyi BR, Machac J. The usefulness of a repeat study for differentiating between bowel activity and local tumor recurrence on FDG PET scans. Clin Nucl Med. 2003;28:672-3.
35. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308-14.
36. Miyake KK, Nakamoto Y, Togashi K. Dual-time-point 18F-FDG PET/CT in patients with colorectal cancer: clinical value of early delayed scanning. Ann Nucl Med. 2012;26:492-500.